Market Overview

Neovasc Broadcasts Surgery With Mitral Valve Device Live At Medical Conference

Neovasc Broadcasts Surgery With Mitral Valve Device Live At Medical Conference

Neovasc Inc (NASDAQ: NVCNannounced after the close Monday that the use of one of its devices was broadcast live at a medical conference. 

What Happened

Neovasc said its Tiara transcatheter mitral valve replacement device was featured in a "Live Case" broadcast at the 32nd Annual European Association for Cardio-Thoracic Surgery Meeting held in Milan, Italy.

Tiara is being developed by Neovasc for treating mitral regurgitation, a condition affecting about 4 million patients in the U.S.

The live broadcast was of two German surgeons successfully implanting a 40nm Tiara transcatheter mitral valve in a patient suffering from severe mitral regurgitation, the company said. 

Why It's Important

The broadcast demonstrated Tiara's potential as a treatment option for patients who are ineligible for open-heart surgical valve replacement.

What's Next

"We look forward to continuing to expand our Tiara clinical program and ultimately the adoption of Tiara for routine use in these patients once regulatory approvals are obtained," Neovasc's CEO Fred Colen said in a statement. 

Neovasc shares were down 1.54 percent at $1.92 at the time of publication Tuesday. 

Related Links:

11 Stocks That Moved From ESMO 2018

The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs

Posted-In: TiaraBiotech News Events Trading Ideas General Best of Benzinga


Related Articles (NVCN)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at